Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19892791 | 1.00 | KDM1A (0.46) | KDM1ACACNA1BRAB9ANPC1ATM | |
| SCHEMBL5620724 | 1.00 | KDM1A (0.46) | KDM1ACACNA1BRAB9ANPC1ATM | |
| SCHEMBL15055360 | 0.88 | KDM1A (0.46) | KDM1ACACNA1BRAB9ANPC1ATM | |
| SCHEMBL5199579 | 0.86 | MAOA (0.47) | KDM1ARAB9ANPC1SIGMAR1MAPT | |
| SCHEMBL15397482 | 0.86 | KDM1A (0.50) | KDM1ACACNA1BRAB9ANPC1ATM | |
| SCHEMBL19893577 | 0.86 | MAOA (0.47) | KDM1ARAB9ANPC1SIGMAR1MAPT | |
| SCHEMBL19893576 | 0.86 | MAOA (0.47) | KDM1ARAB9ANPC1SIGMAR1MAPT | |
| SCHEMBL15397583 | 0.86 | KDM1A (0.50) | KDM1ACACNA1BRAB9ANPC1ATM | |
| SCHEMBL1967275 | 0.86 | MAOA (0.47) | KDM1ARAB9ANPC1SIGMAR1MAPT | |
| SCHEMBL15397555 | 0.86 | KDM1A (0.50) | KDM1ACACNA1BRAB9ANPC1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3530655-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2022-02-09 | — | — | EP | disclosed |
| US-10676461-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-06-09 | — | — | US | disclosed |
| US-20190263784-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-08-29 | — | — | US | disclosed |
| EP-3530655-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10676461-B2 | Heterocyclic compound | SPTLC1, SPTLC3, SPTLC2 | KDM1A 1034/4885CACNA1B 1878/4885RAB9A 717/4885 |
| US-20190263784-A1 | HETEROCYCLIC COMPOUND | SPTLC1, SPTLC3, SPTLC2 | KDM1A 1034/4885CACNA1B 1878/4885RAB9A 717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.